Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial.

Arosio E, De Marchi S, Zannoni M, Prior M, Lechi A

Mayo Clinic proceedings1 Aug 2002Cited by 27 (Europe PMC)

PMID12173710DOI10.4065/77.8.754PepBankPUB-12173710

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, resting posttreatment hemodynamic tests did not differ between glutathione and saline groups.
In plain wordsIn peripheral artery disease, resting circulation tests after treatment did not differ between glutathione and saline groups.
Peptide
Glutathione
Outcome
No significant changeResting posttreatment hemodynamic tests between groups
Study
n = 40
Comparator
Saline solution
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Source sentences
Summary
Between the 2 groups, hemodynamic tests showed no differences in baseline values and at rest after treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371001
02HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, resting hemodynamic values did not differ between baseline and after glutathione treatment.
In plain wordsIn peripheral artery disease, resting circulation values did not differ between baseline and after glutathione treatment.
Peptide
Glutathione
Outcome
No significant changeResting hemodynamic tests versus baseline
Study
n = 20
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Source sentences
Summary
At rest, no differences were observed between basal and posttreatment values
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371002
03HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, glutathione increased pain-free walking distance compared with pretreatment values.
In plain wordsIn peripheral artery disease, glutathione increased pain-free walking distance compared with pretreatment values.
Peptide
Glutathione
Outcome
IncreasePain-free walking distance
Study
n = 20
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Measurements
Pain-free walking distance
196 m
after treatment
Pain-free walking distance
143 m
before treatment
Pain-free walking distance reported +/- uncertainty (type not stated)
15 m
glutathione group after treatment, 196+/-15 m
Pain-free walking distance reported +/- uncertainty (type not stated)
11 m
glutathione group before treatment, 143+/-11 m
P value for pain-free walking distance after versus before treatment
< 0.04
glutathione group, after treatment versus pretreatment
Source sentences
Summary
In the glutathione group, we observed increases in PFWD (196+/-15 vs 143+/-11 m; P<.04)
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371003
04HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, glutathione increased post-treadmill macrocirculatory flow compared with pretreatment values.
In plain wordsIn peripheral artery disease, glutathione increased large-vessel flow after treadmill exercise compared with pretreatment values.
Peptide
Glutathione
Outcome
IncreasePost-treadmill macrocirculatory flow
Study
n = 20
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Measurements
Macrocirculatory flow
9.3 mL per 100 mL/min
after treatment
Macrocirculatory flow
2.8 mL per 100 mL/min
before treatment
Macrocirculatory flow reported +/- uncertainty (type unspecified)
2 mL per 100 mL/min
glutathione group, after treatment
Macrocirculatory flow reported +/- uncertainty (type unspecified)
0.5 mL per 100 mL/min
glutathione group, before treatment
P value
< 0.002
Macrocirculatory flow: glutathione group after treatment versus before treatment
Source sentences
Summary
macrocirculatory flow after treadmill test with plethysmography at the end of treatment (9.3+/-2 vs 2.8+/-0.5 mL per 100 mL/min; P<.002)
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371004
05HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, glutathione increased postischemic hyperemia compared with pretreatment values.
In plain wordsIn peripheral artery disease, glutathione increased blood flow after temporary blood supply restriction compared with pretreatment values.
Peptide
Glutathione
Outcome
IncreasePostischemic hyperemia
Study
n = 20
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Measurements
Postischemic hyperemia
14.4 PU
after treatment
Postischemic hyperemia
6.18 PU
before treatment
Postischemic hyperemia reported +/- uncertainty (type unspecified)
3.2 PU
glutathione group, after treatment
Postischemic hyperemia reported +/- uncertainty (type unspecified)
1.5 PU
glutathione group, before treatment
P value
< 0.005
Postischemic hyperemia: glutathione group after treatment versus before treatment
Source sentences
Summary
and postischemic hyperemia with laser Doppler flowmetry, registered as perfusion units (PU), at the end of infusions (14.4+/-3.2 vs 6.18+/-1.5 PU; P<.005)
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371005
06HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, glutathione increased postischemic hyperemia area under the curve compared with pretreatment values.
In plain wordsIn peripheral artery disease, glutathione increased the total blood flow response after temporary blood supply restriction compared with pretreatment values.
Peptide
Glutathione
Outcome
IncreaseHyperemia area under the curve
Study
n = 20
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Measurements
Hyperemia AUC
705 PU/s
after treatment
Hyperemia AUC
508 PU/s
before treatment
Hyperemia AUC reported +/- uncertainty (type unspecified)
103 PU/s
glutathione group, after treatment
Hyperemia AUC reported +/- uncertainty (type unspecified)
45 PU/s
glutathione group, before treatment
P value
< 0.001
Hyperemia AUC: glutathione group after treatment versus before treatment
Source sentences
Summary
with a greater area under the curve after treatment (705+/-103 vs 508+/-45 PU/s; P<.001)
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371006
07HumanRandomized controlled trialEfficacy outcome
In peripheral artery disease, glutathione reduced time to flow motion compared with pretreatment values.
In plain wordsIn peripheral artery disease, glutathione reduced the time to flow motion compared with pretreatment values.
Peptide
Glutathione
Outcome
DecreaseTime to flow motion
Study
n = 20
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenous twice daily · 5 daysAs given in this study (human).
Measurements
Time to flow motion
32 seconds
after treatment
Time to flow motion
48 seconds
before treatment
Time to flow motion reported +/- uncertainty (type unspecified)
4 seconds
glutathione group, after treatment
Time to flow motion reported +/- uncertainty (type unspecified)
11 seconds
glutathione group, before treatment
P value
< 0.05
Time to flow motion: glutathione group after treatment versus before treatment
Source sentences
Summary
and reduced time to flow motion (32+/-4 vs 48+/-11 seconds; P<.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind, placebo-controlled trial.
Summary · context
The patients were randomly assigned (20 per group) to treatment with intravenous glutathione twice a day or saline solution twice a day for 5 days.
Summary · context
All measurements and tests were repeated 12 hours after the last infusion.
Report a problemFND-1217371007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.